Previous 10 | Next 10 |
Positive Topline Data Reported from argenx's ADHERE Study of VYVGART® Hytrulo with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Chronic Inflammatory Demyelinating Polyneuropathy PR Newswire SAN DIEGO , July 17, 2023 /PRNewswire/ -- Halo...
2023-07-13 09:29:04 ET TG Therapeutics ( NASDAQ: TGTX ), the developer of FDA-approved multiple sclerosis therapy Briumvi, lost ~10% pre-market Thursday after Genentech, a unit of Roche ( OTCQX:RHHBY ) ( OTCQX:RHHBF ), said Thursday that its product Ocrevus reached its m...
Positive Results Announced from Phase 3 OCARINA II Trial Evaluating Roche's OCREVUS® (ocrelizumab) with Halozyme's ENHANZE® Drug Delivery Technology in Patients with Multiple Sclerosis PR Newswire SAN DIEGO , July 13, 2023 /PRNewswire/ -- Halozyme Thera...
2023-07-05 06:24:36 ET Summary argenx's Vyvgart Hytrulo, a game-changer with its 1-minute SC formulation, opens a new revenue stream for Halozyme with sales expected to surpass $10Bn. Despite past headwinds, Vyvgart's SC approval and potential co-formulation patent disclosure coul...
Halozyme Announces argenx Receives FDA Approval for VYVGART® Hytrulo With ENHANZE® for Subcutaneous Use in Generalized Myasthenia Gravis PR Newswire VYVGART® Hytrulo is first FDA-approved subcutaneous (SC) injectable for generalized myasthenia gravis (gMG) ...
2023-06-19 07:44:24 ET Summary Halozyme Therapeutics' valuation has declined, providing a more attractive entry point for investors. The company has multiple royalty-producing products and two new ones awaiting approval in 2023. Halozyme has a strong pipeline of products in de...
Halozyme to Present at the Goldman Sachs 44th Annual Global Healthcare Conference PR Newswire SAN DIEGO , June 6, 2023 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced that Dr. Helen Torley , president and chief executiv...
2023-05-10 09:19:15 ET Halozyme Therapeutics ( NASDAQ: HALO ) moved ~6% higher in the pre-market Wednesday even after recording lower-than-expected financials for Q1 2023 as Piper Sandler upgraded the biotech citing its near-term outlook. Raising his recommendation on...
2023-05-09 20:50:23 ET Halozyme Therapeutics, Inc. (HALO) Q1 2023 Earnings Conference Call May 09, 2023, 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer ...
2023-05-09 16:04:28 ET Halozyme Therapeutics press release ( NASDAQ: HALO ): Q1 Non-GAAP EPS of $0.47 misses by $0.01 . Revenue of $162.14M (+38.2% Y/Y) misses by $13.38M . The 38% year-over-year increase was driven by an increase in royalty revenue primarily a...
News, Short Squeeze, Breakout and More Instantly...
Halozyme Therapeutics Inc. Company Name:
HALO Stock Symbol:
NASDAQ Market:
Halozyme Therapeutics Inc. Website:
Halozyme to Report Second Quarter 2024 Financial and Operating Results PR Newswire SAN DIEGO , July 23, 2024 /PRNewswire/ -- Halozyme Therapeutics, Inc. (NASDAQ: HALO) ("Halozyme") today announced it will release its second quarter 2024 financial and operating re...
2024-07-22 03:26:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...